araag2/HINT huggingface dataset:
Clinical trial NCT00460460 (phase 1, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: azd4877
SMILES: CC(C)C(N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=C(C(C)=NS2)C(=O)N1CC1=CC=CC=C1
Reason stopped: 
    study was terminated due to low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with AML, a certain type of ALL, NHL and MM

          -  certain types of cancer of the lymph nodes

          -  certain types of leukemias (blood cancers)

          -  disease has or will fail with other treatments

          -  relatively good overall health other than your cancer

        Exclusion Criteria:

          -  poor bone marrow function (not producing enough blood cells)

          -  serious heart conditions

          -  poor liver or kidney function
Clinical trial NCT01154881 (phase 1, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months

          -  Body mass index (BMI) below or equal to 35.0 kg/m2

        Exclusion Criteria:

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening

          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent
             per day)

          -  Not able or willing to refrain from smoking and use of nicotine gum or transdermal
             nicotine patches during the inpatient period
Clinical trial NCT01030718 (phase 1/phase 2, status: completed)
Conditions: chronic myelogenous leukemia, philadelphia chromosome positive acute lymphoblastic leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who were eligible and completed the previous Phase I and II study
             (CA180031/NCT00337454) and for whom the principal investigator has deemed that
             continuation of study drug is in the best interest of the subject

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Subjects who are eligible and willing to undergo transplantation at pre-study

          -  Non-hematologic intolerance to Dasatinib (BMS-354825) in the previous Phase I and II
             study (CA180031/NCT00337454)
Clinical trial NCT01527422 (phase 1/phase 2, status: completed)
Conditions: lymphoma, non hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide, doxorubicin, vincristine and prednisone
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with previously untreated aggressive non-Hodgkin's Lymphoma. Aggressive
             histologies include follicular large cell, diffuse large cell, peripheral T cell,
             transformed lymphomas, Lymphoblastic lymphomas, Burkitt and Burkitt like lymphomas.

          -  Must have measurable or evaluable disease.

          -  Stage I-IV patients are eligible

          -  Patients must be 18 years or older.

          -  No evidence of grade 3 or more neurosensory or neuromotor dysfunction (see appendix-
             toxicity criteria)

          -  Written Consent

        Exclusion Criteria:

          -  HIV positive patients and those with Hepatitis B or C will be excluded from this
             protocol.

          -  Patients with inadequate bone marrow and organ function as defined below:

          -  Neutrophils <1,000/l

          -  Platelets <100,000/l

          -  Billirubin >2

          -  Creatinine >2.0 or estimated CrCl <30 cc/min

          -  CNS involvement by Lymphoma.

          -  Uncontrolled intercurrent disease including arrhythmias, angina pectoris, Class III-IV
             Congestive heart failure (CHF symptoms on less than ordinary exertion or at rest) or
             active infection.

          -  Active infection or fever > 38.2 degrees C unless due to lymphoma.

          -  Subject is not using adequate contraceptive precautions.

          -  Pregnancy or breast feeding
Clinical trial NCT01093742 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: hm10560a, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Healthy male volunteers, age range 20 to 54 years are informed of the investigational
             nature of this study and voluntarily agrees to participate in this study

          2. Body mass index of ≥19 and ≤26 Subject

          3. Medically healthy with no clinically significant screening results through Physical
             examination, 12 lead ECG, Laboratory test

          4. Able to participate in all procedure

          5. SBP 90-140 mmHg, DBP 60-90 mmHg, Pulse rate 50-90 times/min

          6. AST, ALT <1.5 X UNL, CPK < 2 X UNL

          7. Able to abstain from alcohol and smoke during study period

          8. Consented to contraception until 2 month after end of the study

        Exclusion Criteria:

          1. Acute infection history within 14 days

          2. Prior exposure or hypersensitivity to recombinant human growth hormone

          3. Positive findings on HBsAg, Anti-HAV IgM, anti-HCV, HIV Ag, HIV Ab and syphilis high
             quality regain test

          4. History of significant gastrointestinal, cardiac, pulmonary, hepato- and nephro-
             disease

          5. psychiatric disorder, malignancy tumor, hormonal disorder, diabetes mellitus and
             hypertension or history of immunosuppressant treatment

          6. Caffeine, alcohol and smoke abuse

          7. History of hemophilia or anticoagulant treatment

          8. Revulsion and/or panic about syringe needle and hypersensitivity to subcutaneously
             administration

          9. History drug abuse or positive testing for amphetamine, barbiturate, cocaine, opiates,
             benzodiazepines

         10. Blood donation or significant blood loss within 60 days prior to Day 1. Plasma
             donation or transfusion within 30 days prior to Day 1.

         11. Receipt of another investigational medication within 60 days prior to Day 1

         12. Use of any herbal products within 30 days or prescription medication within 14 days or
             over-the-counter medication within 7 days prior to the Day 1.

         13. Subjects who are unlikely to comply with the protocol requirements, instructions and
             study related restrictions
Clinical trial NCT00216047 (phase 1/phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ptk787, trastuzumab
SMILES: ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=CC=CC=C23)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    low patient enrollment; toxicities
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of breast cancer with evidence of measurable (1)
             unresectable, locally recurrent, or (2) metastatic disease. Locally recurrent disease
             must not be amenable to resection OR radiation with curative intent.

          -  Patient's disease may not involve more than 3 metastatic sites. In addition, patient
             may not be symptomatic from pulmonary metastasis or have liver metastasis involving >
             50% of parenchyma.

          -  HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry
             will not be sufficient for entry.

          -  Negative pregnancy test

        Exclusion Criteria:

          -  No prior cytotoxic chemotherapy or trastuzumab for locally recurrent or metastatic
             disease.

          -  No prior treatment with any VEGF inhibiting agents

          -  No history or presence of central nervous system (CNS) disease.

          -  No other forms of cancer therapy including radiation, chemotherapy and hormonal
             therapy within 21 days prior to being registered for protocol therapy.

          -  No major surgery within 28 days prior to being registered for protocol therapy.

          -  No uncontrolled hypertension (SBP > 170, DBP > 90), history of labile hypertension or
             history of poor compliance with antihypertensive therapy.

          -  No requirement for therapeutic anticoagulation, regular aspirin (> 325 mg/day) or
             NSAID use.

          -  No current breast feeding.

          -  No impairment of gastrointestinal (GI) function that may significantly alter the
             absorption of PTK787.

          -  No evidence of other serious concomitant systemic disorders incompatible with the
             study (at the discretion of the investigator).
Clinical trial NCT00519298 (phase 1, status: completed)
Conditions: healthy, adult
ICD codes: Z76.3, Z76.2
Drugs: sam-531, donepezil
SMILES: CN(C)CCCOC1=CC=C2NN=C(C2=C1)S(=O)(=O)C1=C2C=CC=CC2=CC=C1, O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women of non-childbearing potential aged 18 to 50 years inclusive on study day
             1.

          -  Body mass index in the range of 18 to 30 kg/m2 and body weight greater than or equal
             to 50 kg.

          -  Healthy as determined by the investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital sign measurements, and 12-lead
             electrocardiogram.

        Exclusion Criteria:

          -  Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal,
             endocrine, immunologic, dermatologic, neurologic, hematologic, neurologic, or
             psychiatric disease.

          -  Clinically significant abnormal standard EEG at screening.

          -  Consumption of any caffeine-containing products or alcoholic beverages within 48 hours
             before study day 1.
Clinical trial NCT00409383 (phase 1, status: unknown status)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: genasense® (oblimersen), abraxane® (paclitaxel protein-bound particles for injectable suspension), temodar® (temozolomide)
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, CN1N=NC2=C(N=CN2C1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with progressive, unresectable, or advanced melanoma who are considered to be
             candidates for systemic treatment with chemotherapy

          -  Subjects will have measurable disease, an Eastern Cooperative Oncology Group
             Performance Status less than or equal to 2, and serum LDH less than or equal to 1.1
             times the upper limit of normal, but will not have previously received cytotoxic
             chemotherapy

          -  Prior immunotherapy, radiotherapy, or cytokine, biologic, or vaccine therapy is
             permitted in the adjuvant and/or metastatic setting

        Exclusion Criteria:

          -  Prior treatment with cytotoxic chemotherapy, including regional perfusion, or with
             Genasense®(oblimersen sodium)Injection

          -  Nonmeasurable disease only

          -  History or presence of brain metastasis or leptomeningeal disease

          -  Significant medical disease other than cancer

          -  Known human immunodeficiency virus infection

          -  Pregnant or lactating

          -  Known hypersensitivity to temozolomide, phosphorothioate-containing oligonucleotides,
             or products containing human albumin

          -  Use of any experimental therapy within 3 weeks prior to baseline evaluations, Other
             anticancer treatment (such as chemotherapy, radiation, or biologic or investigational
             therapies) while receiving therapy in this study
Clinical trial NCT00623649 (phase 1, status: completed)
Conditions: hcv infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: vch 916, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females 18 to 60 years of age

          -  No evidence of cirrhosis or have liver fibrosis corresponding to Metavir Stages 0 to 3

          -  Subject's liver disease is stable with ALT values < 5 X ULN

          -  Serologic evidence of detectable plasma HCV-RNA of ≥ 100,000 IU/ml at screening

          -  Documented HCV Genotype 1 chronic hepatitis C.

          -  Judged to be in good health on the basis of medical history and physical examination

          -  All other hematology and clinical chemistry must be within normal limits or show no
             clinically significant abnormalities.

          -  Be treatment-naïve or experienced.

          -  For female subjects, must not be pregnant or breastfeeding and must be postmenopausal,
             surgically sterile, abstinent, or using two proven methods of birth control.

          -  Sexually active male subjects, must be practicing acceptable methods of contraception
             during the treatment period

          -  Female subjects of childbearing potential must have a negative serum ß-HCG pregnancy
             test at screening and a negative urine pregnancy test on Day 1 before the first dose
             of study drugs.

          -  Agree not to participate in other clinical trials for the duration of his/her
             participation in this clinical trial.

        Exclusion Criteria:

          -  Be participating in any other clinical studies or have participated in another
             clinical trial within the last 30 days before study drug administration, or
             participation in more than 2 drug studies in the last 12 months (exclusive of the
             current study).

          -  Be actively taking hard illicit drugs within 12 months prior to the screening visit or
             alcohol.

          -  Have a Child-Pugh score > than 5.

          -  Have evidence of liver cirrhosis including histological evidence of hepatic cirrhosis
             on any liver biopsy.

          -  Have any cause of liver disease other than chronic hepatitis C-infection

          -  Active or malignant disease or suspicion or history of malignant disease within five
             previous years (except for adequately treated basal cell carcinoma).

          -  Have clinically significant electrocardiogram abnormalities and/or cardiovascular
             dysfunction within the previous 6 months

          -  Have significant renal, pulmonary, gastrointestinal absorption, or neurological
             diseases, or neoplasia.

          -  Have a history of psychiatric disorders determined by the investigator to
             contraindicate therapy.

          -  Have uncontrolled Type 1 or Type II diabetes.

          -  Antinuclear antibody titer ≥1:320.

          -  Coinfection with hepatitis B and/or HIV 1 or HIV 2.
Clinical trial NCT01434225 (phase 1/phase 2, status: completed)
Conditions: neonatal seizures
ICD codes: E71.511, P29.11, P29.12, P29.2, P37.5, P54.0, P54.1
Drugs: bumetanide
SMILES: CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:-

          -  Male or female term baby with gestational age of 37-43 weeks and postnatal age <48
             hours

          -  One or more of the following:

          -  APGAR score < 5 at 5 mins.

          -  Umbilical cord or first arterial blood sample pH < 7.1 or base deficit >16 mmol/L.

          -  Postnatal resuscitation still required 10 minutes after birth

               -  Clinically evolving encephalopathy

               -  Received one dose of standard anticonvulsive therapy (phenobarbitone,20mg/kg) for
                  clinical or electrographic seizures.

               -  EEG: equal to or more than 3 min cumulative seizures, or 2 or more seizures of
                  >30 sec duration over 2 hr period within first 48 hr of life

               -  Written informed consent of parent or guardian.

               -  EEG monitoring has commenced within the first 48 hours of birth.

        Exclusion Criteria:

          -  Suspected or confirmed brain malformation, inborn error of metabolism,genetic
             syndrome, or major congenial malformation

          -  Congenital (in utero) infection (TORCH).

               -  Babies who have received diuretics such as furosemide or bumetanide in routine
                  clinical management within the last 24 hours.

               -  Total serum bilirubin > 15 mg/dl (255 micromol/l) at inclusion.

               -  On any other anticonvulsive medication other than phenobarbitone or bolus of
                  midazolam / pentobarbitone for intubation.

               -  Anuria/renal failure defined as serum creatinine > 200 micromol/l.

               -  Severe electrolyte depletion (Na <120 mmol/L, K <3.0 mmol/L)
Clinical trial NCT01676233 (phase 1, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin glargine (hoe901), insulin glargine- new formulation (hoe901)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria :

          -  Japanese patients with Type 1 Diabetes Mellitus (T1DM) on treatment with basal-bolus
             insulin;

        Exclusion criteria:

          -  Age < 20 years at written informed consent;

          -  HbA1c < 6.5% or > 10.0% at screening

          -  Diabetes mellitus (DM) other than T1DM;

          -  Body Mass Index (BMI) > 35.0 kg/m2 at screening visit

          -  Any contraindication to use of insulin glargine as defined in the Japanese Package
             Insert

          -  Hypoglycemia unawareness or history of metabolic acidosis, including hospitalization
             for diabetic ketoacidosis during the 24 weeks prior to screening visit

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01181310 (phase 1, status: completed)
Conditions: dementia
ICD codes: G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17
Drugs: a: placebo to match donepezil and mk-3134 + placebo to match scopolamine, b: placebo to match donepezil and mk-3134 + scopolamine 0.5 mg, c: mk-3134 25 mg + scopolamine 0.5 mg, d: donepezil 10 mg + scopolamine 0.5 mg, e: combo: donepezil 10 mg + mk-3134 25 mg + scopolamine 0.5 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1, COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1
Eligibility criteria:

        Participants were eligible for inclusion in the study who were:

          -  Male between 18 and 40 years of age.

          -  Non-smokers, in good health (as defined in protocol), and were willing to follow
             study-related procedures.

        Participants were not eligible for inclusion in the study if they:

          -  Had a history of illness that, in the opinion of the study investigator or as
             specified in protocol, might confound the results of the study or posed an potential,
             additional risk to the participant if they were to participate in the study.

          -  Were taking any medication (prescription, nonprescription, vitamin supplements or
             herbal, illicit or legitimate) except for acetaminophen.

          -  Had a history of any significant head injury/trauma.
Clinical trial NCT00445068 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: lbh589
SMILES: [H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO
Eligibility criteria:

        Inclusion criteria:

          1. Adults ≥ 18 years old

          2. Diagnosis of symptomatic multiple myeloma (per IMWG see Kyle et al 2003)

          3. Subjects must have received at least two prior lines of therapy and be refractory to
             the most recent line of therapy

          4. Subjects must have previously been treated with : bortezomib or lenalidomide

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2

          6. Patients must have adequate laboratory values

          7. Baseline left ventricular ejection fraction LVEF ≥ the lower limit of the
             institutional normal

        Exclusion criteria:

          1. Prior therapy with a histone deacetylase inhibitor (HDAC)

          2. Impaired cardiac function or clinically significant cardiac diseases

          3. Impairment of gastrointestinal function (GI) function or GI disease that may
             significantly alter the absorption of LBH589

          4. Patients with unresolved diarrhea > Common Terminology Criteria for Adverse Events
             (CTCAE) grade 1

          5. Concomitant use of certain medications

          6. Patients who have received chemotherapy, radiation therapy or any investigational
             drugs, bortezomib or other immunomodulatory therapy or immunotherapy ≤ 3 weeks prior
             to starting study drug or who have not recovered from side effects of such therapy

          7. Patients who have received steroids ≤ 2 weeks prior to starting study treatment or who
             have not recovered from side effects of such therapy.

          8. Patients who have received high-dose corticosteroids as the only component of their
             most recent line of therapy

          9. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy

         10. Women who are pregnant or breast feeding or women of childbearing potential not using
             an effective method of birth control.

        Other protocol-defined inclusion/exclusion criteria may apply